U.S. markets close in 4 hours 57 minutes

ZyVersa Therapeutics, Inc. (ZVSA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.6399+0.0299 (+1.86%)
As of 10:57AM EDT. Market open.

ZyVersa Therapeutics, Inc.

2200 N. Commerce Parkway
Suite 208
Weston, FL 33326
United States
754 231 1688

Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephen C. GloverCo-Founder, Chairman, CEO & Pres450.5kN/A1960
Mr. Peter WolfeCFO & Sec.275kN/A1968
Mr. Nicholas A. LaBella Jr., MS, RPh.Chief Scientific Officer and Sr. VP of R&D325kN/A1956
Ms. Karen A. CashmereChief Commercial Officer300kN/A1952
Ms. Melda Uzbil O'connellSr. VP of Corp. Devel.N/AN/AN/A
Dr. Pablo A. Guzman FACC, M.D.Chief Medical Officer, Sr. VP of Medical Affairs & Chairman of Renal Scientific Advisory BoardN/AN/A1950
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Corporate Governance

ZyVersa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.